News

PERNIX ESTABLISHES NEW CORPORATE HEADQUARTERS

MORRISTOWN, New Jersey, April 17, 2014 – Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) (NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced it has signed a lease for new corporate headquarters at 10 North Park Place in Morristown, NJ. The new headquarters will be occupied in mid-May and...
Read more

PERNIX AGREES TO DIVEST MANUFACTURING FACILITY

HOUSTON, Texas, April 1, 2014 – Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) (NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced that it has signed a definitive agreement to divest its Houston, TX-based manufacturing operations, Pernix Manufacturing, LLC (“PML”) to Woodfield Pharmaceutical LLC (“Woodfield”). Woodfield will acquire the...
Read more

PERNIX THERAPEUTICS APPOINTS SENIOR VICE PRESIDENT OF SALES AND MARKETING

HOUSTON, Texas, March 18, 2014 – Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) (NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced the appointment of Rick Shalaby as Senior Vice President of Sales and Marketing effective March 17, 2014. Mr. Shalaby brings over twenty-three years of successful industry experience,...
Read more

PERNIX THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2013 FINANCIAL RESULTS

Year over Year Revenue Increased by 38% to $85 Million Quarter over Quarter Revenue Increased by 31.5% to $24 Million Strong Cash Balance To Support Acquisitions HOUSTON, Texas, March 17, 2014 – Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) (NASDAQ: PTX), a specialty pharmaceutical company, today announced financial results...
Read more